Equity Profile

ERAS

Erasca, Inc.

Health CareBiotechnology$3.7B

May11Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Erasca, Inc. Misses on EPS, Stock Up 3.16%

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	-220.86%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Erasca, Inc. Misses on EPS, Stock Up 3.16%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	-220.86%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Erasca, Inc. reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.16%. This could indicate that investors are optimistic about future prospects or other factors not reflected in the earnings figures.

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract customers, crucial for a biotech firm.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as advancements in medical science continue to evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In the last quarter, Erasca reported an EPS of -$0.10, slightly beating expectations. However, the stock reacted negatively, dropping 5.48% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to maintaining cost management strategies.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Erasca's upcoming earnings report, especially given its recent performance. However, uncertainty remains due to the lack of analyst estimates.

Bull Case

If Erasca can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a positive stock reaction.

Bear Case

On the other hand, if the company fails to show meaningful advancements or reports a larger loss than anticipated, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors will closely watch for any advancements, as these could significantly influence the company's future prospects.

How does Erasca plan to manage costs moving forward given the current financial landscape?

Cost management is critical for biotech companies, especially in a challenging market, and could impact profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential impact of recent clinical trial advancements, which could lead to better-than-expected results.

Supporting Evidence

The company's recent trial updates suggest a more favorable outcome than analysts anticipate.

Options pricing indicates a significant move, suggesting that the market is bracing for potential surprises.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its clinical programs while managing costs effectively.

Bull Confirmed If

Positive updates on clinical trials leading to a projected EPS improvement of at least 10% compared to the previous quarter.

Bear Confirmed If

A larger-than-expected EPS loss or negative updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±10.45%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.6% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

213.2%

Calls (16K)P/C Ratio: 0.46Puts (22K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 6 of 16 (38%)

This setup has occurred 30 times across Health Care in the last 2 years. 10 of 16 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.4%, with a raw directional average of +0.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests a modest positive reaction, with an average 1-day move of +1.65% when they beat.

In-Line / Cautious

An in-line report may lead to a muted response, as investors digest management's commentary on future plans.

Miss

If the company misses expectations, history suggests a potential decline of around +6.28% on the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new data.
2Management's outlook on revenue growth and cost management.
3Details on partnerships and collaborations that may enhance product development.
4Any changes to the company's strategic direction or focus areas.
5Insights into market conditions and how they may impact future performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May8

HEReported

Hawaiian Electric Industries, Inc.

RecapView

May8

JHGReported

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract customers, crucial for a biotech firm.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In the last quarter, Erasca reported an EPS of -$0.10, slightly beating expectations. However, the stock reacted negatively, dropping 5.48% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to maintaining cost management strategies.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Erasca's upcoming earnings report, especially given its recent performance. However, uncertainty remains due to the lack of analyst estimates.

Bull Case

If Erasca can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a positive stock reaction.

Bear Case

On the other hand, if the company fails to show meaningful advancements or reports a larger loss than anticipated, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors will closely watch for any advancements, as these could significantly influence the company's future prospects.

How does Erasca plan to manage costs moving forward given the current financial landscape?

Cost management is critical for biotech companies, especially in a challenging market, and could impact profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential impact of recent clinical trial advancements, which could lead to better-than-expected results.

Supporting Evidence

The company's recent trial updates suggest a more favorable outcome than analysts anticipate.

Options pricing indicates a significant move, suggesting that the market is bracing for potential surprises.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its clinical programs while managing costs effectively.

Bull Confirmed If

Positive updates on clinical trials leading to a projected EPS improvement of at least 10% compared to the previous quarter.

Bear Confirmed If

A larger-than-expected EPS loss or negative updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±10.45%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.6% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

213.2%

Calls (16K)P/C Ratio: 0.46Puts (22K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 6 of 16 (38%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests a modest positive reaction, with an average 1-day move of +1.65% when they beat.

In-Line / Cautious

An in-line report may lead to a muted response, as investors digest management's commentary on future plans.

Miss

If the company misses expectations, history suggests a potential decline of around +6.28% on the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials and any new data.
2Management's outlook on revenue growth and cost management.
3Details on partnerships and collaborations that may enhance product development.
4Any changes to the company's strategic direction or focus areas.
5Insights into market conditions and how they may impact future performance.